4). Xenograft mice model assay showed that PPARα agonist clofibrate significantly inhibited tumor growth (Figure 6(a)) and tumor weight (Figure 6(b)). The in vivo tumor tissues further demonstrated that agonist clofibrate reduced Bcl2 protein levels and increased LC3-II levels (Figure 6(c)). These findings suggest that agonist enhanced autophagy-mediated tumor suppression in a PPARα-dependent manner, which was not involved in autophagy-associated gene expressions. Here, BCL2 is linked to neoplasm.